NORTHWEST BIOTHERAPEUTICS ALERT: National Securities Law Firm Announces Filing of Lawsuit on behalf of Northwest Shareholders...

NEW YORK, Aug. 27, 2015 /PRNewswire/ -- Tripp Levy PLLC, a leading national securities law firm, announces that a class action lawsuit has been filed against Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company") (NASDAQ: NWBO) and certain of its officers. The class action, filed in United States District Court, District of Maryland, Greenbelt Division, and docketed under 8:15-cv-02532, is on behalf of a class consisting of all persons or entities who purchased Northwest Biotherapeutics securities between March 8, 2013 and August 20, 2015 inclusive (the "Class Period").

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company's claims regarding positive results from its DCVax-Direct Trial were based on preliminary and unconfirmed trial results; (ii) the DCVax-Direct Trial results on which the Company reported had not been reviewed or analyzed by the hospitals conducting the trials; (iii) the Company's statements about DCVax-Direct were derived from patient case report forms, which the hospitals were obliged to send to the Company only because it sponsored the study; (iv) the Company was the subject of an aggressive stock promotion campaign which included promoters using fictitious identities and false credentials; (v) German regulators required additional information from the Company in order for the Company's DCVax-L Trial to continue uninterrupted; and (vi) as a result of the above, the Company's financial statements were materially false and misleading at all relevant times.

If you purchased shares of Northwest and have suffered a loss from your investment in Northwest common stock and would like to learn more about this lawsuit, including your ability to potentially recover your losses, please contact us either by email at [e-mail] or by telephone at [phone] or visit our website at www.tripplevy.com/participate-in-an-action.  In addition, if you wish to serve as a representative party, you must move the Court no later than 60 days from the date of the filing of the Complaint.  You can join this class action to potentially recover your losses by contacting us at www.tripplevy.com/participate-in-an-action.

Tripp Levy PLLC is a leading national securities and shareholder rights law firm representing both individual and institutional shareholders and, along with its affiliate, have recovered billions of dollars for shareholders. Tripp Levy PLLC is affiliated with Milberg LLP.  The National Law Journal has named Milberg one of the "50 Elite Trial Lawyer Firms" and one of the "50 Leading Plaintiff Firms in America."

Attorney advertising.  Prior results do not indicate a similar outcome.

Tripp Levy PLLC 
New York, New York 
Toll free: 800-511-7037 
International: 602-241-2841 
Email: [e-mail]   
www.tripplevy.com  

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/northwest-biotherapeutics-alert-national-securities-law-firm-announces-filing-of-lawsuit-on-behalf-of-northwest-shareholders-to-recover-losses-and-encourages-investors-to-contact-law-firm-for-more-information-300134102.html

SOURCE Tripp Levy PLLC

Copyright 2015 PR Newswire